Solid Biosciences (SLDB) announced a non-exclusive worldwide license and collaboration agreement with Andelyn Biosciences, a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization, CDMO, for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Under the terms of the agreement, Solid grants Andelyn a non-exclusive worldwide license to provide its gene therapy clients with access to utilize AAV-SLB101 in combination with Andelyn’s suspension and adherent modular platform process, the AAV Curator Platform, which brings a modular approach to gene therapy CMC processes by optimizing manufacturing and using configurable materials. Specific financial terms of the agreement have not been disclosed.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences announces SGT-003 granted an Innovation Passport under ILAP
- Solid Biosciences price target lowered to $11 from $13 at JPMorgan
- Solid Biosciences price target lowered to $14 from $16 at Citi
- Solid Biosciences Faces Regulatory and Financial Challenges Amid FDA Disruptions
- Solid Biosciences’ SGT-003 Therapy Shows Promising Efficacy and Safety, Earning a Buy Rating